DISINTEGRIN AND METALLOPROTEINASE DOMAIN-CONTAINING PROTEIN 17

US Previously Marketed

First approved in 1951

Description
Sources: https://www.drugbank.ca/drugs/DB00269
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68002741

Chlorotrianisene (TACE®) is a powerful synthetic, non-steroidal estrogen used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. It may also be used to prevent breast engorgement following childbirth. Chlorotrianisene (TACE®) binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Estrogen receptor 72 Target ID: CHEMBL2094114 Sources: https://www.drugbank.ca/drugs/DB00269	Modulator 846

Conditions

Condition	Modality	Highest Phase	Product
Menopause 4 Sources: https://www.drugbank.ca/drugs/DB00269	Palliative	Approved 8583	TACE Approved Use Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.
Deficiencies in ovary function 2 Sources: https://www.drugbank.ca/drugs/DB00269	Curative	Approved 8583	TACE Approved Use Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.
Prostate cancer 186 Sources: https://www.drugbank.ca/drugs/DB00269	Palliative	Approved 8583	TACE Approved Use Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.
Breast engorgement 2 Sources: https://www.drugbank.ca/drugs/DB00269	Preventing	Approved 8583	TACE Approved Use Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.

Doses

Dose	Population	Adverse events
72 mg 2 times / day multiple, oral Dose: 72 mg, 2 times / day Route: oral Route: multiple Dose: 72 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/453287	healthy, 21 years Health Status: healthy Age Group: 21 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/453287	Sources: https://pubmed.ncbi.nlm.nih.gov/453287

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3641	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3641
ChemicalBook	CB9321078	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9321078
eMolecules	536400	https://www.emolecules.com/cgi-bin/more?vid=536400
MolPort	MolPort-001-783-515	https://www.molport.com/shop/molecule-link/MolPort-001-783-515
ZINC	ZINC000001530598	http://zinc15.docking.org/substances/ZINC000001530598

PubMed

Title	Date	PubMed
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.	2013-09-05	23769903
Treatments for suppression of lactation.	2009-01-21	19160258
An inventory of yeast proteins associated with nucleolar and ribosomal components.	2006	17067374
Tracing the origins of COX-2 inhibitors' structures.	2002-08	12173976
The effect of chlorotrianisene as postpartum lactation suppression on blood coagulation factors.	1979-07-01	453287
The choice of estrogen preparations in the treatment of prostatic cancer.	1975-11-08	1182631
Hydroxyurea in stage D carcinoma of the prostate: a pilot study.	1975-09	1142528

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

In Vitro Use Guide

Rat pituitary gland cells (2 x 10^5/dish) were cultured for 8 days with medium containing chlorotrianisene (TACE) or its demethylated derivative, 1,1,2-tri(4-hydroxyphenyl)chloroethylene (TCE), alone or with E2 (0.1 or 1 nM). TCE was a partial estrogen with antiestrogenic properties against E2 (0.1 nM). The antiestrogenic effect could also be reversed by increasing the concentration of E2 10-fold. TACE was less estrogenic and a less potent E2 antagonist.

Substance Class	Protein Created by `admin` on `Tue Apr 01 17:04:44 GMT 2025` Edited by `admin` on `Tue Apr 01 17:04:44 GMT 2025`
Protein Type	PEPTIDE
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	37OV8A66E1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ADAM17

Preferred Name

English

DISINTEGRIN AND METALLOPROTEINASE DOMAIN-CONTAINING PROTEIN 17

Common Name

English

TNF-ALPHA CONVERTASE

Common Name

English

TNF-ALPHA-CONVERTING ENZYME

Common Name

English

SNAKE VENOM-LIKE PROTEASE

Common Name

English

TACE

Common Name

English

Code System Code Type Description

UNIPROT

P78536

Created by admin on Tue Apr 01 17:04:44 GMT 2025 , Edited by admin on Tue Apr 01 17:04:44 GMT 2025

PRIMARY

DAILYMED

37OV8A66E1

Created by admin on Tue Apr 01 17:04:44 GMT 2025 , Edited by admin on Tue Apr 01 17:04:44 GMT 2025

PRIMARY

FDA UNII

37OV8A66E1

Created by admin on Tue Apr 01 17:04:44 GMT 2025 , Edited by admin on Tue Apr 01 17:04:44 GMT 2025

PRIMARY

From	To
1_11	1_119
1_151	1_255
1_209	1_239
1_320	1_341
1_359	1_368
1_364	1_377
1_379	1_386

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_50
N	1_238
N	1_284
N	1_325
N	1_337
N	1_380

Related Record Type Details


					BK349F52C9

BATIMASTAT

INHIBITOR -> TARGET

Comments:

It also potently inhibits TNF?-converting enzyme (IC50 = 14.9 nM).

Qualification:

IC50

Amount:


					V9YL6NEJ3G

ADERBASIB

INHIBITOR -> TARGET

Amount:


					80AXY59IT2

CGS-27023

INHIBITOR->OFF-TARGET

Qualification:

IC50

Amount:


					C6BZ5263BJ

APRATASTAT

INHIBITOR -> TARGET

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_553] [1_577] [1_605]	SITE_SPECIFIC	S		DEXFOSFOSERINE	VI4F0K069V
AMINO_ACID_SUBSTITUTION	[1_521] [1_547]	SITE_SPECIFIC	T		THREONINE PHOSPHATE	3L4WX7B1EI

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT	CHEMICAL

DescriptionSources: https://www.drugbank.ca/drugs/DB00269Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68002741

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

Approved Use

Doses

Sourcing

PubMed

Patents

Sample Use Guides

Structural Modifications

Description
Sources: https://www.drugbank.ca/drugs/DB00269
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68002741